Adage Capital Partners Gp, L.L.C. Merus N.V. Transaction History
Adage Capital Partners Gp, L.L.C.
- $56.4 Billion
- Q2 2025
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Merus N.V. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 833,397 shares of MRUS stock, worth $53.1 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
833,397Holding current value
$53.1 Million% of portfolio
0.08%Shares
7 transactions
Others Institutions Holding MRUS
# of Institutions
217Shares Held
65.3MCall Options Held
311KPut Options Held
556K-
Paradigm Biocapital Advisors LP New York, NY4.28MShares$273 Million10.51% of portfolio
-
Rtw Investments, LP New York, NY4MShares$255 Million3.23% of portfolio
-
Wellington Management Group LLP Boston, MA3.73MShares$238 Million0.04% of portfolio
-
Commodore Capital LP New York, NY3.53MShares$225 Million17.29% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.38MShares$216 Million4.09% of portfolio
About Merus N.V.
- Ticker MRUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,878,200
- Market Cap $2.93B
- Description
- Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...